Anoxic Brain Injury
Conditions
Keywords
Anoxic Brain Injury, Autologous bone marrow derived stem cell, stoke
Brief summary
The purpose of study is to evaluate the safety and efficacy of autologous bone marrow-derived stem cells therapy in patients with anaerobic (hypoxic) brain injury. Stem cell therapy is an emerging alternative treatment modality in incurable and intractable neurological disorders. This pilot study aims to evaluate the feasibility and safety of stem cells in anaerobic brain injury.
Detailed description
Various treatment modalities to minimize the neurological deficits of anoxic brain injury, including lower consciousness, abnormal movement disorders, and abnormal behavior, have been tried, but so far there have been no effective proven method for chronic patients. This study is the investigator initiated trial to verify the safety and feasibility of stem cells therapy in patients with anoxic brain injury.
Interventions
BIOLOGICALHYNR-CS inj.
Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
Sponsors
Hyun Young Kim
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Patients older than 14 days after the index event occurs in an oxygen-free brain injury patients * Severe disability or moderate due to anoxic brain injury * 18 years to 75 years * Patients was 7 points less than Glasgow coma scale (GCS) After the resumption of blood flow circulation. * anaerobic unexpected (hypoxic) cerebral ischemia Encephalopathy (It should not be a hypoxic brain ischemia was induced due to heart surgery, which is scheduled) * Subjects agreed in writing that it will be participating in clinical research, as viewed from the legal representative (patient)
Exclusion criteria
* Patients who require ventilator continued * Patients who had extracorporeal membrane oxygenation(ECMO) index event occurs at the time * Patients who had a history of cardiac arrest prior to the occurrence of Index event * End-stage people of less than 12 months is expected (incurable) disease patients * Patients with cardiac arrest occurred due to brain trauma severe * Patients with damage to other organs of severe * Patients with bleeding or malignant current * Pregnant patient * Patients with central nervous system tumors undergoing radiation therapy or chemotherapy * If the patient or are participating in other clinical trials, you are planning to participate, or patients three months after the end is not passed to participate in other clinical trials
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| safety assessment | week 1, 3, 4, 5, 7 | Each visit physical examination, neurological examination, and adverse reactions through the follow-up to the expression of new symptoms. week 1,3,5,7 conducted Hematological week 4,7 conducted MRI, PET |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Glasgow Coma Scale(GCS) | Week 1, 4, 5, 6, 7 | assess level of consciousness after head injury |
| FOUR score | Week 1, 4, 5, 6, 7 | The FOUR Score is a clinical grading scale designed for use by medical professionals in the assessment of patients with impaired level of consciousness. |
| Functional Independence Measure(FIM) | Week 1, 4, 5, 6, 7 | The Functional Independence Measure (FIM™) instrument is a basic indicator of patient disability. |
| Disability Rating Scale(DRS) | Week 1, 4, 5, 6, 7 | The Disability Rating Scale (DRS) is primarily used to assess impairment, disability, and handicap of an individual. |
| Cerebral Performance Category(CPC)scale | Week 1, 4, 5, 6, 7 | The Cerebral Performance Category score is to use measure of functional outcome after cardiac arrest. |
Countries
South Korea
Contacts
Primary ContactHyun Young Kim, MD,. PhD.
Outcome results
None listed